Form 4: AbCellera Biologics Inc. Executive Receives Share Options
SEC Form 4 Filing
Veronique Lecault, Chief Operating Officer of AbCellera Biologics Inc., was granted 832,033 share options on January 1, 2025.
Summary
- Veronique Lecault, the Chief Operating Officer of AbCellera Biologics Inc., received 832,033 share options on January 1, 2025.
- These options have an exercise price of $2.93 per share.
- The options vest monthly over a four-year period, starting January 1, 2026, contingent on Ms. Lecault's continued employment with the company.
- The options expire on January 1, 2035.
- Following this transaction, Ms. Lecault directly owns 4,661,804 derivative securities.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The granting of share options to the COO aligns her interests with the long-term success of the company.
- The vesting schedule encourages continued service and commitment from the executive.
Future Outlook
The share options will vest over the next four years, subject to the COO's continued employment.
Industry Context
The granting of share options is a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Share option grants are a standard form of compensation for executives in the biotech industry, often used to align management's interests with shareholders.
- Vesting schedules, like the four-year monthly vesting in this case, are typical to encourage long-term commitment.
- The exercise price of $2.93 is a key factor, as it determines the potential value of the options for the executive.
Stakeholder Impact
- Shareholders may view the share option grant positively as it incentivizes the COO to contribute to the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Date of the share option grant. |
| 01/01/2026 | Start date for monthly vesting of the share options. |
| 01/01/2035 | Expiration date of the share options. |
| 01/03/2025 | Date of the filing of the form. |
Keywords
share options, executive compensation, insider trading, AbCellera Biologics, biotechnology, stock options, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.